The effects of forodesine in murine and human multiple myeloma cells

Advances in Hematology

Volumn 2010, Issue , 2010, Pages

  Bieghs, Liesbeth ^a   Caers, Jo ^b   De Bruyne, Elke ^a   Van Valckenborgh, Els ^a   Higginbotham, Fiona ^c   Vanderkerken, Karin ^a   Menu, Eline ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Mundipharma Research Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; DEOXYGUANOSINE TRIPHOSPHATE; FORODESINE; PROTEIN P27;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

EID: 78349273651     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2010/131895     Document Type: Article

References (28)

1. Caers J., Vande Broek I., De Raeve H., Michaux L., Trullemans F., Schots R., Van Camp B., Vanderkerken K., Multiple myelomaan update on diagnosis and treatment European Journal of Haematology 2008 81 5 329 343
2. Galmarini C. M., Popowycz F., Joseph B., Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy Current Medicinal Chemistry 2008 15 11 1072 1082
3. Kicska G. A., Long L., Hrig H., Fairchild C., Tyler P. C., Furneaux R. H., Schramm V. L., Kaufman H. L., Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes Proceedings of the National Academy of Sciences of the United States of America 2001 98 8 4593 4598
4. Bantia S., Miller P. J., Parker C. D., Ananth S. L., Horn L. L., Kilpatrick J. M., Morris P. E., Hutchison T. L., Montgomery J. A., Sandhu J. S., Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)a novel potent and orally active immunosuppressive agent International Immunopharmacology 2001 1 6 1199 1210
5. Bantia S., Ananth S. L., Parker C. D., Horn L. L., Upshaw R., Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitorBCX-1777 International Immunopharmacology 2003 3 6 879 887
6. Balakrishnan K., Nimmanapalli R., Ravandi F., Keating M. J., Gandhi V., Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells Blood 2006 108 7 2392 2398
7. Alonso R., Lpez-Guerra M., Upshaw R., Bantia S., Smal C., Bontemps F., Manz C., Mehrling T., Villamor N., Campo E., Montserrat E., Colomer D., Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM Blood 2009 114 8 1563 1575
8. Kuroda J., Taniwaki M., Involvement of BH3-only proteins in hematologic malignancies Critical Reviews in Oncology/Hematology 2009 71 2 89 101
9. Homminga I., Zwaan C. M., Manz C. Y., Bantia S., Parker C., Buijs-Gladdines J., Smits W., Horstmann M. A., Pieters R., Meijerink J. P. P., In-vitro efficacy of the deoxyguanoside analogs forodesine (BCX-1777) and ARA-G in pediatric acute lymphoblastic leukemia ASH Annual Meeting Abstracts 2009 114 22 2038
10. Duvic M., Forero-Torres A., Foss F., Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I/II study Blood 2006 108 11 698a
11. Duvic M., Foss F., Olsen E., Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma Blood 2004 104 11 683a
12. Furman R. R., Gandhi W., Bennett J. C., Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia Blood 2004 104 11 750a
13. Furman R. R., Iosava G., Isola L., Forodesine (FodosineTM), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients(phase II study) Blood 2005 106 11 259a
14. Gandhi V., Kilpatrick J. M., Plunkett W., Ayres M., Harman L., Du M., Bantia S., Davisson J., Wierda W. G., Faderl S., Kantarjian H., Thomas D., A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine) Blood 2005 106 13 4253 4260
15. Robak T., Korycka A., Ewa L.-M., Robak P., Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases Molecules 2009 14 3 1183 1226
16. Robak T., Korycka A., Kasznicki M., Wrzesien-Kus A., Smolewski P., Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications Current Cancer Drug Targets 2005 5 6 421 444
17. Kraut E. H., Crowley J. J., Grever M. R., Keppen M. D., Bonnet J. D., Hynes H. E., Salmon S. E., Phase II study of fludarabine phosphate in multiple myeloma. A Southwest oncology group study Investigational New Drugs 1990 8 2 199 200
18. Dimopoulos M. A., Kantarjian H. M., Estey E. H., Alexanian R., 2-Chlorodeoxyadenosine in the treatment of multiple myeloma Blood 1992 80 6 1626
19. Bjrkstrand B., Rasmussen T., Remes K., Gruber A., Pelliniemi T.-T., Johnsen H. E., Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study European Journal of Haematology 2003 70 6 379 383
20. Asosingh K., Radl J., Van Riet I., Van Camp B., Vanderkerken K., The 5TMM series: a useful in vivo mouse model of human multiple myeloma Hematology Journal 2000 1 5 351 356
21. Asosingh K., De Raeve H., Croucher P., Goes E., Van Riet I., Van Camp B., Vanderkerken K., In vivo homing and differentiation characteristics of mature (CD45 -) and immature (CD45 +) 5T multiple myeloma cells Experimental Hematology 2001 29 1 77 84
22. Pickering J. W., Gelder F. B., A human myeloma cell line that does not express immunoglobulin but yields a high frequency of antibody-secreting hybridomas Journal of Immunology 1982 129 1 406 412
23. Srivastava B. I. S., Minowada J., Terminal deoxynucleotidyl transferase activity in a cell line (Molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia Biochemical and Biophysical Research Communications 1973 51 3 529 535
24. Menu E., Garcia J., Huang X., Di Liberto M., Toogood P. L., Chen I., Vanderkerken K., Chen-Kiang S., A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model Cancer Research 2008 68 14 5519 5523
25. Menu E., Valckenborgh E. V., Camp B. V., Vanderkerken K., The role of the insulin-like growth factor 1 receptor axis in multiple myeloma Archives of Physiology and Biochemistry 2009 115 2 49 57
26. Chen-Kiang S., Cell-cycle control of plasma cell differentiation and tumorigenesis Immunological Reviews 2003 194 39 47
27. Jourdan M., Reme T., Goldschmidt H., Fiol G., Pantesco V., De Vos J., Rossi J.-F., Hose D., Klein B., Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells British Journal of Haematology 2009 145 1 45 58
28. Huang M., Wang Y., Gu J., Yang J., Noel K., Mitchell B. S., Schramm V. L., Graves L. M., Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H Leukemia Research 2008 32 8 1268 1278